WO2005072306A3 - Reelin deficiency or dysfunction and methods related thereto - Google Patents

Reelin deficiency or dysfunction and methods related thereto Download PDF

Info

Publication number
WO2005072306A3
WO2005072306A3 PCT/US2005/002177 US2005002177W WO2005072306A3 WO 2005072306 A3 WO2005072306 A3 WO 2005072306A3 US 2005002177 W US2005002177 W US 2005002177W WO 2005072306 A3 WO2005072306 A3 WO 2005072306A3
Authority
WO
WIPO (PCT)
Prior art keywords
patient
reelin
dysfunction
deficiency
dha
Prior art date
Application number
PCT/US2005/002177
Other languages
French (fr)
Other versions
WO2005072306A2 (en
Inventor
John P Morseman
Mark W Moss
Lorie A Ellis
Original Assignee
Martek Biosciences Corp
John P Morseman
Mark W Moss
Lorie A Ellis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Martek Biosciences Corp, John P Morseman, Mark W Moss, Lorie A Ellis filed Critical Martek Biosciences Corp
Priority to AU2005208832A priority Critical patent/AU2005208832A1/en
Priority to US10/597,304 priority patent/US20090215896A1/en
Priority to JP2006551363A priority patent/JP2007524674A/en
Priority to CA002551882A priority patent/CA2551882A1/en
Priority to EP05706056A priority patent/EP1713463A4/en
Publication of WO2005072306A2 publication Critical patent/WO2005072306A2/en
Publication of WO2005072306A3 publication Critical patent/WO2005072306A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A method of measuring Reelin as a biomarker, to non-destructively assess or predict DHA levels in the brain and in other, currently inaccessible or difficult-to-access, key components of the central nervous system (CNS) is described. Also described is a method to prevent, delay the onset of, or treat Reelin deficiency or dysfunction and/or a disease or condition associated with Reelin deficiency or dysfunction, comprising administering to a patient diagnosed with or suspected of having a Reelin deficiency or dysfunction an amount of a PUFA, and particularly an omega-3 PUFA, and more particularly, docosahexaenoic acid (DHA) or a precursor or source thereof, to compensate for the effects of Reelin deficiency or dysfunction in the patient. Also described is a method to prevent or reduce development defects or disorders associated with Reelin dysfunction or deficiency through the supplemental use of polyunsaturated fatty acids (PUFAs- unsaturated fatty acids having two or more double bonds), and particularly highly unsaturated fatty acids (HUFAs- unsaturated fatty acids having three or more double bonds), and more particularly a HUFA selected from arachidonic acid (ARA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA), and even more particularly omega-3 HUFAs, and more particularly DHA, to: compensate for reduced fatty acid binding protein or function thereof in the patient; compensate for reduced brain lipid binding protein or function thereof in the patient; improve the activity of fatty acid binding proteins in the patient; increase the expression of brain lipid binding proteins (BLBPs) in the patient; improve at least one parameter of the mechanism of action of brain lipid binding proteins in the patient; overcome a deficiency of DHA in central nervous system (CNS) structures and improve the resulting function thereof; increase the incorporation of functional DHA and other PUFAs into the phospholipid membranes of glial cells and neurons in the patient; increase the level of Reelin and/or improve the activity of Reelin in the patient; and/or improve at least one symptom of a disease or condition associated with Reelin deficiency or dysfunction.
PCT/US2005/002177 2004-01-19 2005-01-19 Reelin deficiency or dysfunction and methods related thereto WO2005072306A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2005208832A AU2005208832A1 (en) 2004-01-19 2005-01-19 Reelin deficiency or dysfunction and methods related thereto
US10/597,304 US20090215896A1 (en) 2004-01-19 2005-01-19 Reelin deficiency or dysfunction and methods related thereto
JP2006551363A JP2007524674A (en) 2004-01-19 2005-01-19 Reelin deficiency or dysfunction and related methods
CA002551882A CA2551882A1 (en) 2004-01-19 2005-01-19 Reelin deficiency or dysfunction and methods related thereto
EP05706056A EP1713463A4 (en) 2004-01-19 2005-01-19 Reelin deficiency or dysfunction and methods related thereto

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US53760004P 2004-01-19 2004-01-19
US60/537,600 2004-01-19
US60521904P 2004-08-27 2004-08-27
US60/605,219 2004-08-27

Publications (2)

Publication Number Publication Date
WO2005072306A2 WO2005072306A2 (en) 2005-08-11
WO2005072306A3 true WO2005072306A3 (en) 2006-03-09

Family

ID=34830449

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/002177 WO2005072306A2 (en) 2004-01-19 2005-01-19 Reelin deficiency or dysfunction and methods related thereto

Country Status (6)

Country Link
US (1) US20090215896A1 (en)
EP (1) EP1713463A4 (en)
JP (1) JP2007524674A (en)
AU (1) AU2005208832A1 (en)
CA (1) CA2551882A1 (en)
WO (1) WO2005072306A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003048831A (en) 2001-08-02 2003-02-21 Suntory Ltd Composition having preventing and ameliorating action on symptom or disease caused by decrease in brain function
JP4993852B2 (en) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 Composition having a preventive or ameliorating effect on symptoms or diseases accompanied by behavioral abnormalities caused by stress
MX2007005435A (en) * 2004-11-08 2007-07-24 Univ Duke Biomarker for heart failure.
JP5697293B2 (en) * 2005-06-30 2015-04-08 サントリーホールディングス株式会社 Composition having an improving effect on lowering of higher brain function due to organic brain injury
JP5967855B2 (en) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 Composition having an activity of reducing daytime activity and / or depressive symptoms
KR101870626B1 (en) * 2005-07-08 2018-06-26 디에스엠 아이피 어셋츠 비.브이. Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions
KR101578498B1 (en) 2006-12-28 2015-12-18 산토리 홀딩스 가부시키가이샤 Nerve regeneration agent
WO2010045490A2 (en) * 2008-10-15 2010-04-22 Ridge Diagnostics, Inc. Human biomarker hypermapping for depressive disorders
AU2010313249B2 (en) 2009-10-30 2016-05-19 Biojiva Llc Alleviating oxidative stress disorders with PUFA derivatives
US20130184173A1 (en) * 2010-04-14 2013-07-18 The Royal Institution For The Advancement Of Learning/Mcgill University Biomarkers for multiple sclerosis
AU2012249917B2 (en) 2011-04-26 2017-06-15 Biojiva Llc Neurodegenerative disorders and muscle diseases implicating PUFAs
AU2012249921B2 (en) * 2011-04-26 2017-06-08 Biojiva Llc Oxidative retinal diseases
CA2834343C (en) 2011-04-26 2021-10-12 Retrotope, Inc. Disorders implicating pufa oxidation
EA201491540A8 (en) * 2012-02-17 2016-07-29 Алкреста, Инк. METHODS, COMPOSITIONS, AND DEVICES FOR MEETING FOOD NEEDS FOR FATTY ACID
CN103820528B (en) * 2012-11-16 2015-02-18 北京大学 New applications of Reelin and antagonist thereof in staging and prognosis of myeloma patient
KR102390107B1 (en) 2013-05-30 2022-04-25 그라함 에이치. 크리시 Topical neurological stimulation
US11229789B2 (en) 2013-05-30 2022-01-25 Neurostim Oab, Inc. Neuro activator with controller
US11077301B2 (en) 2015-02-21 2021-08-03 NeurostimOAB, Inc. Topical nerve stimulator and sensor for bladder control
US10258590B2 (en) 2015-10-14 2019-04-16 Alcresta Therapeutics, Inc. Enteral feeding device and related methods of use
US10730821B2 (en) 2015-11-23 2020-08-04 Retrotope, Inc. Site-specific isotopic labeling of 1,4-diene systems
US11045396B2 (en) 2017-08-17 2021-06-29 Alcresta Therapeutics, Inc. Devices and methods for the supplementation of a nutritional formula
EP3700935A4 (en) * 2017-10-25 2021-08-04 University Of South Florida Drug-induced activation of the reelin signaling system
EP3706856A4 (en) 2017-11-07 2021-08-18 Neurostim Oab, Inc. Non-invasive nerve activator with adaptive circuit
CN114126704A (en) 2019-06-26 2022-03-01 神经科学技术有限责任公司 Non-invasive neural activator with adaptive circuit
JP2023506713A (en) 2019-12-16 2023-02-20 ニューロスティム テクノロジーズ エルエルシー Noninvasive nerve activator using booster charge delivery
WO2021168311A1 (en) 2020-02-21 2021-08-26 Retrotope, Inc. Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516800A (en) * 1992-11-26 1996-05-14 Scotia Holdings Plc Schizophrenia
US6197764B1 (en) * 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
CA2010511A1 (en) * 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids
CA2052577C (en) * 1991-10-01 2000-01-11 Michael John Tisdale Therapeutic uses of eicosapentaenoic acid
GB9510636D0 (en) * 1995-05-25 1995-07-19 Scotia Holdings Plc Fatty acid treatment
IL122405A (en) * 1995-06-07 2003-04-10 Martek Biosciences Corp Methods for preparation of pharmaceutical composition for treatment of specific diseases using oils enriched in dha
GB9617847D0 (en) * 1996-08-27 1996-10-09 Scotia Holdings Plc Fatty acid treatment
PL190181B1 (en) * 1996-10-11 2005-11-30 Scarista Ltd Pharmaceutic preparation containing eicosapentaenic acid and/or stearidonic acid
JPH10139675A (en) * 1996-11-05 1998-05-26 Otsuka Yakuhin Kogyo Kk Production of agent for allowing brain to be healthy and vital
AU7222598A (en) * 1997-04-29 1998-11-24 Scotia Holdings Plc Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants
JP2003508487A (en) * 1999-09-09 2003-03-04 イーエフエイ サイエンシーズ エルエルシー． Methods for treating cell proliferative disorders, including cancer
US6380253B1 (en) * 2000-01-05 2002-04-30 Efa Sciences Llc Method of stabilizing and potentiating the action of anti-angiogenic substances
AU2634101A (en) * 2000-01-06 2001-07-16 Martek Biosciences Corporation Therapeutic preparations of highly unsaturated fatty acids
US7208180B2 (en) * 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
GB0016045D0 (en) * 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
US20020077317A1 (en) * 2000-12-15 2002-06-20 Das Undurti Narasimha Method of potentating the action of 2-methoxyoestradiol, statins and C-peptide of proinsulin
CA2449199A1 (en) * 2001-05-30 2002-12-05 Laxdale Limited Coenzyme q and eicosapentaenoic acid (epa)
JP2003048831A (en) * 2001-08-02 2003-02-21 Suntory Ltd Composition having preventing and ameliorating action on symptom or disease caused by decrease in brain function
US20030165485A1 (en) * 2001-11-09 2003-09-04 Goran Bertilsson Functional role and potential therapeutic use of Reelin, Gas6 and Protein S in relation to adult neural stem or progenitor cells
NL1019368C2 (en) * 2001-11-14 2003-05-20 Nutricia Nv Preparation for improving receptor performance.
US7341844B2 (en) * 2002-01-16 2008-03-11 Regents Of The University Of Minnesota Methods for diagnosing autism
WO2004012753A1 (en) * 2002-07-31 2004-02-12 Helfried Hans Rudolf Crede Pharmaceutical composition containing black cumin oil, flax oil and borago oil
GB0228079D0 (en) * 2002-12-02 2003-01-08 Laxdale Ltd Huntington's Disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516800A (en) * 1992-11-26 1996-05-14 Scotia Holdings Plc Schizophrenia
US6197764B1 (en) * 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1713463A4 *

Also Published As

Publication number Publication date
EP1713463A4 (en) 2009-03-18
CA2551882A1 (en) 2005-08-11
WO2005072306A2 (en) 2005-08-11
US20090215896A1 (en) 2009-08-27
EP1713463A2 (en) 2006-10-25
AU2005208832A1 (en) 2005-08-11
JP2007524674A (en) 2007-08-30

Similar Documents

Publication Publication Date Title
WO2005072306A3 (en) Reelin deficiency or dysfunction and methods related thereto
Kurlak et al. Plausible explanations for effects of long chain polyunsaturated fatty acids (LCPUFA) on neonates
Igarashi et al. Disturbed choline plasmalogen and phospholipid fatty acid concentrations in Alzheimer's disease prefrontal cortex
Dyall Interplay between n-3 and n-6 long-chain polyunsaturated fatty acids and the endocannabinoid system in brain protection and repair
Tian et al. Brain histological changes in young mice submitted to diets with different ratios of n-6/n-3 polyunsaturated fatty acids during maternal pregnancy and lactation
Young et al. Blood phospholipid fatty acid analysis of adults with and without attention deficit/hyperactivity disorder
Contreras et al. Nutritional deprivation of α‐linolenic acid decreases but does not abolish turnover and availability of unacylated docosahexaenoic acid and docosahexaenoyl‐CoA in rat brain
Hamilton et al. Brain uptake and utilization of fatty acids, lipids and lipoproteins: application to neurological disorders
Boudrault et al. Experimental models and mechanisms underlying the protective effects of n-3 polyunsaturated fatty acids in Alzheimer's disease
Yamamoto et al. Effect of the dietary alpha-linolenate/linoleate balance on lipid compositions and learning ability of rats. II. Discrimination process, extinction process, and glycolipid compositions.
Yamashima ‘PUFA–GPR40–CREB signaling’hypothesis for the adult primate neurogenesis
Hashimoto et al. Neuroprotective and ameliorative actions of polyunsaturated fatty acids against neuronal diseases: beneficial effect of docosahexaenoic acid on cognitive decline in Alzheimer’s disease
BRPI0418921A (en) use of polyunsaturated fatty acids, nutritional composition, and use of a
Igarashi et al. Dietary n-6 PUFA deprivation for 15 weeks reduces arachidonic acid concentrations while increasing n-3 PUFA concentrations in organs of post-weaning male rats
Liperoti et al. Omega-3 polyunsaturated fatty acids and depression: a review of the evidence
Tateishi et al. Dietary supplementation of arachidonic acid increases arachidonic acid and lipoxin A 4 contents in colon, but does not affect severity or prostaglandin E 2 content in murine colitis model
Levant et al. Reduced brain DHA content after a single reproductive cycle in female rats fed a diet deficient in N-3 polyunsaturated fatty acids
Tuazon et al. Fatty acid profile of skeletal muscle phospholipid is altered in mdx mice and is predictive of disease markers
Morgese et al. N-3 PUFA diet enrichment prevents amyloid beta-induced depressive-like phenotype
Mauro et al. Fatty acids in normal and pathological pregnancies
Yoshinaga et al. Selective visualization of administrated arachidonic and docosahexaenoic acids in brain using combination of simple stable isotope-labeling technique and imaging mass spectrometry
Dyall Amyloid-beta peptide, oxidative stress and inflammation in alzheimer's disease: Potential neuroprotective effects of omega-3 polyunsaturated fatty acids
Stachowicz Application potential of modulation of cyclooxygenase-2 activity: a cognitive approach
Zhao et al. Study of the serum levels of polyunsaturated fatty acids and the expression of related liver metabolic enzymes in a rat valproate-induced autism model
Peet Essential fatty acids: theoretical aspects and treatment implications for schizophrenia and depression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2005208832

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2551882

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2005208832

Country of ref document: AU

Date of ref document: 20050119

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005208832

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 10597304

Country of ref document: US

Ref document number: 2006551363

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005706056

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200580008876.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2005706056

Country of ref document: EP